Loading..

Ionis Pharmaceuticals, Inc. (IONS) Report Analysis

Corporate Events

Positive

Ionis Pharmaceuticals, Inc. Announces Presentat...

2022-06-25 13:05:00

Ionis Pharmaceuticals, Inc. announced that GSK presented positive results from an interim analysis of the Phase 2b B-Clear clinical study of b...

Positive

Ionis Announces Eplontersen Met Co-Primary and ...

2022-06-21 06:00:00

Ionis Pharmaceuticals, Inc. announced positive topline results from a 35-week interim analysis of the Phase 3 NEURO-TTRansform study of Ionis ...

Positive

Ionis Pharmaceuticals, Inc. Announces Results f...

2022-06-03 09:20:00

Ionis Pharmaceuticals, Inc. announced results from the Phase 3 VALOR study and its open-label extension (OLE) of tofersen, an investigational ...

Neutral

Ionis Pharmaceuticals, Inc. - Special Call

2022-06-01 00:00:00

To discuss Virtual Corporate Presentation

Neutral

Ionis Pharmaceuticals, Inc. Presents at DIA Glo...

2022-05-28 18:13:00

Ionis Pharmaceuticals, Inc. Presents at DIA Global Annual Meeting 2022, Jun-19-2022 . Venue: Chicago, Illinois, United States. Speakers: Krist...

Neutral

Ionis Pharmaceuticals, Inc. Presents at RBC Cap...

2022-05-12 11:10:00

Ionis Pharmaceuticals, Inc. Presents at RBC Capital Markets Global Healthcare Conference, May-18-2022 08:30 AM. Venue: InterContinental New Yo...

Neutral

Ionis Pharmaceuticals, Inc. Presents at TIDES (...

2022-04-23 17:57:00

Ionis Pharmaceuticals, Inc. Presents at TIDES (Oligonucleotide & Peptide Therapeutics), May-05-2022 . Venue: Boston, Massachusetts, United Sta...

Neutral

I.I.R Ltd., TIDES (Oligonucleotide & Peptide Th...

2022-04-23 07:45:00

I.I.R Ltd., TIDES (Oligonucleotide & Peptide Therapeutics), May 05, 2022 through May 12, 2022. Venue: Boston, Massachusetts, United States.

Neutral

I.I.R Ltd., TIDES (Oligonucleotide & Peptide Th...

2022-04-23 07:45:00

I.I.R Ltd., TIDES (Oligonucleotide & Peptide Therapeutics), May 05, 2022 through May 12, 2022. Venue: Boston, Massachusetts, United States.

Neutral

Ionis Pharmaceuticals, Inc., Annual General Mee...

2022-04-20 16:23:00

Ionis Pharmaceuticals, Inc., Annual General Meeting, Jun 02, 2022, at 14:00 Pacific Standard Time. Agenda: To consider electing nominees, Alle...

Neutral

Ionis Pharmaceuticals, Inc. - Shareholder/Analyst Call

2022-04-20 16:23:00

Annual Meeting of Stockholders

Neutral

Ionis Pharmaceuticals, Inc., Q1 2022 Earnings C...

2022-04-20 11:05:00

Ionis Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 04, 2022

Positive

Ionis and Astrazeneca Announce Positive Data fo...

2022-04-04 04:15:00

Ionis Pharmaceuticals, Inc. and its partner, AstraZeneca PLC announced positive data from the ETESIAN Phase 2b study of ION449 (AZD8233), an i...

Neutral

Ionis Pharmaceuticals, Inc. Presents at America...

2022-04-04 04:15:00

Ionis Pharmaceuticals, Inc. Presents at American College of Cardiology Annual Scientific Session & Expo, Apr-01-2022 . Venue: Washington, Dist...

Neutral

Ionis Pharmaceuticals, Inc. Presents at Wells F...

2022-03-29 20:00:00

Ionis Pharmaceuticals, Inc. Presents at Wells Fargo Annual Biotech Forum, Apr-12-2022 . Venue: Miami, Florida, United States. Speakers: Elizab...

Neutral

Wells Fargo Securities, LLC, Wells Fargo Annual...

2022-03-29 11:02:00

Wells Fargo Securities, LLC, Wells Fargo Annual Biotech Forum, Apr 12, 2022 through Apr 13, 2022. Venue: Miami, Florida, United States.

Neutral

Ionis Pharmaceuticals, Inc. Presents at Guggenh...

2022-03-21 11:05:00

Ionis Pharmaceuticals, Inc. Presents at Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Day, Apr-01-2022 01:00 PM.

Neutral

Ionis Pharmaceuticals, Inc. Presents at Needham...

2022-03-21 11:05:00

Ionis Pharmaceuticals, Inc. Presents at Needham 21st Annual Healthcare Conference, Apr-11-2022 10:15 AM.

Neutral

Ionis Pharmaceuticals, Inc. Presents at Bank of...

2022-03-21 11:05:00

Ionis Pharmaceuticals, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2022 10:00 AM. Venue: Encore Hotel, 3121 Las Vegas ...

Neutral

RBC Capital Markets, LLC, RBC Capital Markets G...

2022-03-04 01:06:00

RBC Capital Markets, LLC, RBC Capital Markets Global Healthcare Conference, May 17, 2022 through May 18, 2022. Venue: InterContinental New Yor...

Neutral

Guggenheim Securities, LLC, Guggenheim Healthca...

2022-02-24 12:30:00

Guggenheim Securities, LLC, Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Day, Mar 31, 2022 through Apr 01, 2022.

Neutral

Bank of America Corporation, Bank of America 20...

2022-02-17 10:42:00

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022. Venue: Encore Hotel, 3121 Las Vega...

Neutral

Needham & Company, LLC, Needham 21st Annual Hea...

2022-02-11 23:04:00

Needham & Company, LLC, Needham 21st Annual Healthcare Conference, Apr 11, 2022 through Apr 14, 2022.

Neutral

Ionis Pharmaceuticals, Inc. Presents at SCOPE S...

2022-02-04 08:35:00

Ionis Pharmaceuticals, Inc. Presents at SCOPE Summit 2022, Feb-09-2022 09:55 AM. Venue: Orlanda, Florida, United States. Speakers: Eugene Schn...

Positive

Ionis Pharmaceuticals, Inc. Announce Discontinu...

2022-01-31 12:33:00

Pfizer Inc. and Ionis Pharmaceuticals, Inc. announced the discontinuation of the Pfizer-led clinical development program for vupanorsen (PF-07...

Positive

Pfizer and Ionis Pharmaceuticals, Inc Announce ...

2022-01-31 12:05:00

Pfizer Inc. and Ionis Pharmaceuticals, Inc. announced the discontinuation of the Pfizer-led clinical development program for vupanorsen (PF-07...

Neutral

American College of Cardiology, Inc., American ...

2022-01-26 12:00:00

American College of Cardiology, Inc., American College of Cardiology Annual Scientific Session & Expo, Apr 01, 2022 through Apr 04, 2022. Venu...

Positive

Biogen Inc. Exercises Option with Ionis Pharmac...

2022-01-04 12:34:00

Biogen Inc. and Ionis Pharmaceuticals, Inc. announced that Biogen exercised its option to obtain from Ionis a worldwide, exclusive, royalty-be...

Positive

Ionis Pharmaceuticals, Inc. and Astrazeneca Clo...

2021-12-29 07:00:00

Ionis Pharmaceuticals, Inc. announced the closing of the collaboration agreement with AstraZeneca to develop and commercialize eplontersen, Io...

Neutral

Drug Information Association, Inc., DIA Global ...

2021-12-10 06:32:00

Drug Information Association, Inc., DIA Global Annual Meeting 2022, Jun 19, 2022 through Jun 23, 2022. Venue: Chicago, Illinois, United States.

Neutral

Ionis Pharmaceuticals, Inc. - Special Call

2021-12-07 07:00:00

To discuss the announcement related to strategic collaboration agreement with AstraZeneca to develop and commercialize eplontersen and related...

Positive

AstraZeneca and Ionis Pharmaceuticals, Inc. to ...

2021-12-07 07:00:00

AstraZeneca has entered into a new global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. (Ionis) for eplontersen...

Neutral

Ionis Pharmaceuticals, Inc. - Analyst/Investor Day

2021-12-02 20:03:00

To provide an overview of its strategy, plans, and progress to bring its most advanced programs to market and achieve commercial success as we...

Negative

Ionis Pharmaceuticals, Inc. Announces Resignati...

2021-11-26 21:06:00

On November 19, 2021, Peter N. Reikes, a member of the Board of Directors (‘Board’) and Finance Committee of the Board of Ionis Pharmaceutical...

Positive

Ionis Announces That Pfizer Reports Topline Res...

2021-11-24 11:30:00

Ionis Pharmaceuticals Inc. announced that Pfizer has provided an update on the Phase 2b study of vupanorsen, formerly IONIS-ANGPTL3-LRx. Vupan...

Positive

Ionis Pharmaceuticals, Inc. Initiates Phase 3 C...

2021-11-18 18:30:00

Ionis Pharmaceuticals, Inc. announced initiation of OASIS-HAE, the registrational study in the donidalorsen (formerly IONIS-PKK-LRx) Phase 3 c...

Neutral

Ionis Pharmaceuticals, Inc. Presents at Access ...

2021-11-12 05:15:00

Ionis Pharmaceuticals, Inc. Presents at Access Insights Conference 2021, Nov-15-2021 . Speakers: Paul Voss, Executive Director, Market Access ...

Neutral

Ionis Pharmaceuticals, Inc. Presents at 4th Ann...

2021-11-09 12:08:00

Ionis Pharmaceuticals, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov-30-2021 10:30 AM.

Neutral

Ionis Pharmaceuticals, Inc. Presents at Stifel ...

2021-11-09 12:08:00

Ionis Pharmaceuticals, Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-15-2021 10:40 AM. Venue: New York, New York, United States.

Positive

Ionis Pharmaceuticals, Inc. Announces That Posi...

2021-11-07 12:05:00

Ionis Pharmaceuticals, Inc. announced that positive results from the Phase 2 study of its investigational antisense medicine, donidalorsen, wi...

Positive

Ionis Pharmaceuticals, Inc. Initiates Pivotal P...

2021-11-02 11:05:00

Ionis Pharmaceuticals, Inc. announced on November 2, 2021, the initiation of CORE, the second Phase 3 clinical study of olezarsen, formerly kn...

Neutral

Ionis Pharmaceuticals, Inc., Q3 2021 Earnings C...

2021-10-20 11:05:00

Ionis Pharmaceuticals, Inc., Q3 2021 Earnings Call, Nov 03, 2021

Neutral

Informa plc, TIDES EUROPE: Oligonucleotide & Pe...

2021-10-12 20:23:00

Informa plc, TIDES EUROPE: Oligonucleotide & Peptide Therapeutics, Nov 15, 2021 through Nov 17, 2021.

Neutral

Ionis Pharmaceuticals, Inc. Presents at TIDES E...

2021-10-12 20:23:00

Ionis Pharmaceuticals, Inc. Presents at TIDES EUROPE: Oligonucleotide & Peptide Therapeutics, Nov-15-2021 through Nov-17-2021. Presentation Da...

Neutral

Ionis Pharmaceuticals, Inc. Presents at 2nd Dry...

2021-10-12 18:27:00

Ionis Pharmaceuticals, Inc. Presents at 2nd Dry AMD Therapeutic Development Summit, Oct-19-2021 . Speakers: Michael McCaleb, Vice President, C...

Neutral

Hanson Wade Limited, 2nd Dry AMD Therapeutic De...

2021-10-12 06:27:00

Hanson Wade Limited, 2nd Dry AMD Therapeutic Development Summit, Oct 19, 2021 through Oct 21, 2021.

Neutral

Ionis Pharmaceuticals, Inc. Presents at Interna...

2021-09-30 20:47:00

Ionis Pharmaceuticals, Inc. Presents at International Oligonucleotide and Peptide Conference, Oct-19-2021 04:55 PM. Speakers: Richard S. Geary...

Neutral

Tekno Scienze S.R.L., International Oligonucleo...

2021-09-30 20:01:00

Tekno Scienze S.R.L., International Oligonucleotide and Peptide Conference, Oct 18, 2021 through Oct 19, 2021.

Neutral

Ionis Pharmaceuticals, Inc. Presents at Longwoo...

2021-09-28 18:44:00

Ionis Pharmaceuticals, Inc. Presents at Longwood Healthcare Leaders Conference, Oct-05-2021 01:30 PM. Speakers: Brett P. Monia, Founder, CEO &...

Neutral

Longwood Fund, Longwood Healthcare Leaders Conf...

2021-09-28 13:09:00

Longwood Fund, Longwood Healthcare Leaders Conference, Oct 04, 2021 through Oct 05, 2021.

Neutral

Ionis Pharmaceuticals, Inc. Presents at 17th An...

2021-09-24 16:33:00

Ionis Pharmaceuticals, Inc. Presents at 17th Annual Meeting of the Oligonucleotide Therapeutics Society, Sep-26-2021 . Speakers: Holly Kordasi...

Neutral

Ionis Pharmaceuticals, Inc. Presents at Second ...

2021-09-15 16:12:00

Ionis Pharmaceuticals, Inc. Presents at Second Annual Undruggable Leaders Forum, Sep-15-2021 04:20 PM. Speakers: Shuling Guo, Vice President, ...

Neutral

GreyGreen, Second Annual Undruggable Leaders Fo...

2021-09-15 11:32:00

GreyGreen, Second Annual Undruggable Leaders Forum, Sep 15, 2021 through Sep 16, 2021.

Positive

Flamingo Therapeutics, Inc. Expands Alliance wi...

2021-09-09 12:00:00

Flamingo Therapeutics, Inc. announced that it has entered into an agreement with Ionis Pharmaceuticals to develop RNA-targeted therapies to tr...

Neutral

OLIGONUCLEOTIDE THERAPEUTICS SOCIETY INC, 17th ...

2021-09-04 15:00:00

OLIGONUCLEOTIDE THERAPEUTICS SOCIETY INC, 17th Annual Meeting of the Oligonucleotide Therapeutics Society, Sep 26, 2021 through Sep 29, 2021.

Neutral

Cambridge Innovation Institute, LLC, SCOPE Summ...

2021-09-04 12:00:00

Cambridge Innovation Institute, LLC, SCOPE Summit 2022, Feb 07, 2022 through Feb 10, 2022. Venue: Orlanda, Florida, United States.

Neutral

Ionis Pharmaceuticals, Inc., 3rd European ATTR ...

2021-09-03 11:34:00

Ionis Pharmaceuticals, Inc., 3rd European ATTR Amyloidosis meeting, Sep 06, 2021 through Sep 08, 2021.

Neutral

Ionis Pharmaceuticals, Inc., 3rd European ATTR ...

2021-09-03 11:34:00

Ionis Pharmaceuticals, Inc., 3rd European ATTR Amyloidosis meeting, Sep 06, 2021 through Sep 08, 2021.

Neutral

Ionis Pharmaceuticals, Inc. Presents at 3rd Eur...

2021-09-03 11:34:00

Ionis Pharmaceuticals, Inc. Presents at 3rd European ATTR Amyloidosis meeting, Sep-06-2021 through Sep-08-2021. Presentation Date & Speakers: ...

Neutral

Ionis Pharmaceuticals, Inc. Presents at Morgan ...

2021-09-02 11:05:00

Ionis Pharmaceuticals, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-13-2021 02:00 PM. Venue: New Windsor, Uni...

Neutral

Ionis Pharmaceuticals, Inc. Presents at Bank of...

2021-09-02 11:05:00

Ionis Pharmaceuticals, Inc. Presents at Bank of America Global Healthcare Conference, Sep-15-2021 10:55 AM. Speakers: Elizabeth L. Hougen, Exe...

Neutral

Evercore Inc., 4th Annual Evercore ISI HealthCO...

2021-08-24 20:29:00

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.

Neutral

Ionis Pharmaceuticals, Inc. Presents at World O...

2021-08-20 20:24:00

Ionis Pharmaceuticals, Inc. Presents at World Orphan Drug Congress USA 2021, Aug-27-2021 03:20 PM. Venue: Gaylord National Resort & Convention...

Neutral

Terrapinn Holdings Ltd, World Orphan Drug Congr...

2021-08-20 17:31:00

Terrapinn Holdings Ltd, World Orphan Drug Congress USA 2021, Aug 25, 2021 through Aug 27, 2021. Venue: Gaylord National Resort & Convention C...

Neutral

Ionis Pharmaceuticals, Inc. Presents at 5th Ann...

2021-08-10 14:19:00

Ionis Pharmaceuticals, Inc. Presents at 5th Annual IPF Summit, Aug-26-2021 04:00 PM. Speakers: Jeff Crosby, Director of Pulmonary Drug Discovery.

Neutral

Hanson Wade Limited, 5th Annual IPF Summit, Aug...

2021-08-10 12:54:00

Hanson Wade Limited, 5th Annual IPF Summit, Aug 25, 2021 through Aug 27, 2021.

Neutral

Ionis Pharmaceuticals, Inc. has filed a Shelf R...

2021-08-05 00:00:00

Ionis Pharmaceuticals, Inc. has filed a Shelf Registration in the amount of $253.327 million. Security Name: Common Stock Securities Offer...

Negative

Ionis Pharmaceuticals, Inc. Provides Earnings G...

2021-08-04 15:16:00

Ionis Pharmaceuticals, Inc. provided earnings guidance for the full year 2021. For the year, the company on track to achieve revenue of $600 m...

Positive

Ionis Pharmaceuticals, Inc. Continues to Advanc...

2021-08-02 13:30:00

Ionis Pharmaceuticals, Inc. announced that pelacarsen, formerly known as AKCEA-APO(a)-LRx, and licensed by Novartis for exclusive worldwide de...

Positive

Ionis Pharmaceuticals, Inc. Completes Enrollmen...

2021-07-29 11:05:00

Ionis Pharmaceuticals, Inc. announced it has completed enrollment of NEURO-TTRansform, the company's Phase 3 study of eplontersen, formerly AK...

Positive

Biogen Inc. and Ionis Pharmaceuticals, Inc. Ann...

2021-07-26 20:35:00

Biogen Inc. and Ionis Pharmaceuticals, Inc. announced that topline data from a Phase 1b placebo-controlled, multiple ascending dose clinical s...

Neutral

Ionis Pharmaceuticals, Inc. Presents at Wells F...

2021-07-22 14:24:00

Ionis Pharmaceuticals, Inc. Presents at Wells Fargo 2021 Virtual Healthcare Conference, Sep-10-2021 02:00 PM. Speakers: Brett P. Monia, Founde...

Neutral

Wells Fargo Securities, LLC, Wells Fargo 2021 V...

2021-07-22 09:08:00

Wells Fargo Securities, LLC, Wells Fargo 2021 Virtual Healthcare Conference, Sep 09, 2021 through Sep 10, 2021.

Neutral

Ionis Pharmaceuticals, Inc., Q2 2021 Earnings C...

2021-07-21 11:05:00

Ionis Pharmaceuticals, Inc., Q2 2021 Earnings Call, Aug 04, 2021

Neutral

BicycleTx Limited and Ionis Pharmaceuticals, In...

2021-07-13 11:54:00

On July 9, 2021, BicycleTx Limited and Ionis Pharmaceuticals, Inc. entered into a collaboration and license agreement (the “Collaboration Agre...

Neutral

Ionis Enters Exclusive Licensing Agreement with...

2021-07-13 10:59:00

Ionis Pharmaceuticals, Inc. announced that it has entered into an exclusive licensing agreement with Bicycle Therapeutics plc to increase the ...

Neutral

Bicycle Therapeutics Enters Exclusive License a...

2021-07-13 10:59:00

Bicycle Therapeutics plc announced that Ionis Pharmaceuticals has exercised its option and entered into an exclusive worldwide license and col...

Positive

Bicycle Therapeutics plc announced that it expe...

2021-07-09 00:00:00

Bicycle Therapeutics plc announced that it has entered into a share purchase agreement with new investor Ionis Pharmaceuticals, Inc. for priva...

Neutral

Stifel, Nicolaus & Company, Incorporated, Stife...

2021-07-08 08:44:00

Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021. Venue: New York, New ...

Positive

Ionis Pharmaceuticals, Inc. Announces Presentation of Positive Phase 2B Data for Chronic Hepatitis B Treatment At the EASL International Liver Congress™

2022-06-25 13:05:00

Ionis Pharmaceuticals, Inc. announced that GSK presented positive results from an interim analysis of the Phase 2b B-Clear clinical study of bepirovirsen (formerly IONIS-HBVRx), an investigational antisense medicine for the treatment of patients with chronic hepatitis B virus (CHB). The data were presented in an oral late-breaker session at the European Association for the Study of the Liver's (EASL) International Liver Congress™ 2022 in London, UK. The final results from the study will be submitted for presentation at a scientific congress later this year, and for publication in a peer-reviewed journal. In the study, 28% of patients on standard of care, which is stable nucleoside/nucleotide analogue (NA), and 29% of patients not on NA treatment, experienced a virologic response (VR) on 300 mg of bepirovirsen weekly, following 24 weeks of treatment. Virologic response is defined as serum/plasma levels of hepatitis B virus (HBV) DNA and hepatitis B surface antigens (HBsAg) below the lower limit of quantification. Up to 68% of patients on NA therapy and up to 65% of patients not on NA achieved HBsAg <100 IU/mL at the end of treatment. End-of-treatment virologic responses were observed in patients with high or low baseline HBsAg levels, who were hepatitis B e-antigen (HBeAg) negative or positive, and who were receiving NA treatment or not, indicating that bepirovirsen has the potential to treat broad segments of the CHB population. Durability of the responses is being assessed.Treatment-related serious adverse events (SAEs) were observed in <1% of patients receiving NA treatment and 1% of patients who were not on NA. SAEs were reported in 3% and 4% of patients receiving NA treatment and those who were not on NA, respectively. There were no clinically meaningful differences in adverse events across treatment arms in either trial. Currently, nucleoside/nucleotide analogues are the recommended first-line therapy for patients with chronic HBV because they can inhibit viral replication. However, they cannot clear the virus and must be taken for life. Bepirovirsen is uniquely designed to reduce HBV replication and suppress HBsAg which could potentially lead to functional cure, largely defined as sustained, undetectable levels of hepatitis B virus DNA and HBsAg in the blood with or without generating protective antibodies after a finite course of treatment.GSK is also exploring combinations of bepirovirsen and other therapeutic modalities in the following trials. Combination treatments could increase functional cure rates in more patients, thereby further reducing the global disease burden of CHB. Trials include: Phase 2b trial of bepirovirsen in sequential combination with pegylated interferon (PegIFN) treatment. Phase 2 trial of bepirovirsen in combination with GSK's chronic hepatitis B targeted immunotherapy. The B-Clear Phase 2b study is investigating the efficacy and safety of 12- or 24-weeks treatment with bepirovirsen in people living with CHB on stable NA treatment or not on NA treatment at study start. The primary endpoints are the proportion of patients achieving HBsAg levels below the Lower Limit of Quantification (LLOQ), and HBV DNA levels below LLOQ sustained for 24 weeks without rescue medication after end of treatment with bepirovirsen.The study consists of two parallel cohorts, one for patients receiving NA treatment and the other for patients who were not on NA. Patients from each arm were randomized to 1 of 4 treatment arms within each cohort, with treatment administered weekly with or without loading doses (LD) on days 4 and 11: Bepirovirsen 300 mg with LD for 24 weeks; Bepirovirsen 300 mg with LD for 12 weeks then 150 mg for 12 weeks; Bepirovirsen 300 mg with LD for 12 weeks then placebo for 12 weeks; Placebo with LD for 12 weeks then bepirovirsen 300 mg without LD for 12 weeks. In both cohorts, virologic responses were observed at the end of treatment: For those patients receiving NA treatment (n=227), 24 weeks treatment of 300 mg bepirovirsen weekly resulted in HBsAg < LLOQ and HBV DNA < LLOQ in 28% of patients at end of treatment. For patients not on NA (n=230), 24 weeks treatment of 300 mg bepirovirsen weekly resulted in HBsAg < LLOQ and HBV DNA < LLOQ in 29% of patients at end of treatment. The durability of these responses is being assessed.

Positive

Ionis Announces Eplontersen Met Co-Primary and Secondary Endpoints in Interim Analysis of the Phase 3 Neuro-Ttransform Study for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (Attrv-Pn)

2022-06-21 06:00:00

Ionis Pharmaceuticals, Inc. announced positive topline results from a 35-week interim analysis of the Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca's eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). Eplontersen demonstrated a statistically significant and clinically meaningful change from baseline for the co-primary endpoints of percent change in serum transthyretin (TTR) concentration and the modified Neuropathy Impairment Score +7 (mNIS+7), a measure of neuropathic disease progression, versus the historical placebo group. Eplontersen also met its key secondary endpoint of change from baseline in the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QoL-DN), showing treatment with eplontersen significantly improved patient-reported quality of life versus the historical placebo group. In the study, eplontersen demonstrated a favorable safety and tolerability profile with no specific concerns. The study data are consistent with the clinical profile seen across Ionis' other LICA programs, further validating how advancements in the company's LIgand-Conjugated Antisense technology position Ionis to deliver potentially transformative treatments for a range of unmet medical needs. Based on these study results, the companies will seek regulatory approval for eplontersen for ATTRv-PN and plan to file a new drug application with the U.S. Food and Drug Administration this year. As part of a global development and commercialization agreement between Ionis and AstraZeneca, eplontersen is being jointly developed and commercialized by both companies in the U.S. and will be developed and commercialized in the rest of the world by AstraZeneca (with the exception of Latin America). Eplontersen was granted Orphan Drug Designation in the U.S. It is also currently being evaluated in the Phase 3 CARDIO-TTRansform study for amyloid transthyretin cardiomyopathy (ATTR-CM), a systemic, progressive and fatal condition that leads to progressive heart failure and death within four years from diagnosis.

Positive

Ionis Pharmaceuticals, Inc. Announces Results from the Phase 3 Valor Study and Its Open-Label Extension of tofersen

2022-06-03 09:20:00

Ionis Pharmaceuticals, Inc. announced results from the Phase 3 VALOR study and its open-label extension (OLE) of tofersen, an investigational antisense medicine being evaluated for people with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). The data show that earlier initiation of tofersen, compared to delayed initiation, slowed declines in clinical function, respiratory function, muscle strength and quality of life. At the time of the analysis, because the majority of participants survived without permanent ventilation (PV), the median time to death or PV could not be estimated. However, early survival data suggest a lower risk of death or PV with earlier initiation of tofersen. These results are based on new integrated data from the VALOR pivotal study and its OLE study. The results were presented at the European Network to Cure ALS (ENCALS) meeting in Edinburgh, Scotland. As previously reported in October 2021, VALOR, a six-month Phase 3 randomized study, did not meet the primary endpoint of change from baseline to week 28 in the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R). However, trends of reduced disease progression across multiple secondary and exploratory endpoints were observed. The new 12-month data further build on the results previously observed in the initial readout. The 12-month data compare early initiation of tofersen (at the start of VALOR) to delayed initiation of tofersen (six months later, in the OLE). Over 12 months in the overall study population, results favored earlier start tofersen on measures of: Clinical function as measured by ALSFRS-R (difference of 3.5 points; 95% confidence interval [CI]: 0.4, 6.7). Respiratory function as measured by slow vital capacity (difference of 9.2 percent-predicted; 95% CI: 1.7, 16.6). Muscle strength as measured by the handheld dynamometry megascore (difference of 0.28; 95% CI: 0.05, 0.52). Quality of life as measured by the 5-item amyotrophic lateral sclerosis assessment questionnaire (ALSAQ-5) (difference of 10.3 points; 95% CI: -17.3, -3.2). At the time of the analysis, because the majority of participants survived without permanent ventilation (PV), the median time to death or PV and median time to death, could not be estimated. However, early survival data suggest a lower risk of death or PV (Hazard ratio [HR] 0.36; 95% CI: 0.137, 0.941) and death (HR 0.27; 95% CI: 0.084, 0.890) with earlier initiation of tofersen.

Neutral

Ionis Pharmaceuticals, Inc. - Special Call

2022-06-01 00:00:00

To discuss Virtual Corporate Presentation

Neutral

Ionis Pharmaceuticals, Inc. Presents at DIA Global Annual Meeting 2022, Jun-19-2022

2022-05-28 18:13:00

Ionis Pharmaceuticals, Inc. Presents at DIA Global Annual Meeting 2022, Jun-19-2022 . Venue: Chicago, Illinois, United States. Speakers: Kristina Bowyer, Vice President of Patient Advocacy.

Neutral

Ionis Pharmaceuticals, Inc. Presents at RBC Capital Markets Global Healthcare Conference, May-18-2022 08:30 AM

2022-05-12 11:10:00

Ionis Pharmaceuticals, Inc. Presents at RBC Capital Markets Global Healthcare Conference, May-18-2022 08:30 AM. Venue: InterContinental New York, Barclay hotel, New York, New York, United States.

Neutral

Ionis Pharmaceuticals, Inc. Presents at TIDES (Oligonucleotide & Peptide Therapeutics), May-05-2022

2022-04-23 17:57:00

Ionis Pharmaceuticals, Inc. Presents at TIDES (Oligonucleotide & Peptide Therapeutics), May-05-2022 . Venue: Boston, Massachusetts, United States. Speakers: Brett P. Monia, Founder, CEO & Director, Sotirios Tsimikas, Senior VP of ClinDev & CV Franchise Leader.

Neutral

I.I.R Ltd., TIDES (Oligonucleotide & Peptide Therapeutics), May 05, 2022 through May 12, 2022

2022-04-23 07:45:00

I.I.R Ltd., TIDES (Oligonucleotide & Peptide Therapeutics), May 05, 2022 through May 12, 2022. Venue: Boston, Massachusetts, United States.

Neutral

I.I.R Ltd., TIDES (Oligonucleotide & Peptide Therapeutics), May 05, 2022 through May 12, 2022

2022-04-23 07:45:00

I.I.R Ltd., TIDES (Oligonucleotide & Peptide Therapeutics), May 05, 2022 through May 12, 2022. Venue: Boston, Massachusetts, United States.

Neutral

Ionis Pharmaceuticals, Inc., Annual General Meeting, Jun 02, 2022

2022-04-20 16:23:00

Ionis Pharmaceuticals, Inc., Annual General Meeting, Jun 02, 2022, at 14:00 Pacific Standard Time. Agenda: To consider electing nominees, Allene M. Diaz, Michael Hayden, Joseph Klein, III, and Joseph Loscalzo, to board of directors to serve as directors for a three-year term; to make an advisory vote on executive compensation; and to ratify the audit committee’s selection of Ernst & Young LLP as independent auditors for 2022 fiscal year; and to transact any other business that may be properly presented at the annual meeting.

Neutral

Ionis Pharmaceuticals, Inc. - Shareholder/Analyst Call

2022-04-20 16:23:00

Annual Meeting of Stockholders

Neutral

Ionis Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 04, 2022

2022-04-20 11:05:00

Ionis Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 04, 2022

Positive

Ionis and Astrazeneca Announce Positive Data for Etesian Phase 2B Study of Antisense Medicine Targeting PCSK9 at 2022 American College of Cardiology Scientific Session

2022-04-04 04:15:00

Ionis Pharmaceuticals, Inc. and its partner, AstraZeneca PLC announced positive data from the ETESIAN Phase 2b study of ION449 (AZD8233), an investigational antisense medicine designed to reduce blood cholesterol levels in patients with hypercholesterolemia by targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). These data were presented at the American College of Cardiology's 71st Annual Scientific Session & Expo. The ETESIAN Phase 2b study's objective was to assess the efficacy, safety and tolerability of ION449 in patients with high-risk hypercholesterolemia. The study met its primary endpoint in reducing serum LDL-C levels by up to 79%. Both the 50mg and 90mg doses reached statistically significant and clinically meaningful reductions in LDL-C levels from baseline of 73% (95% confidence interval [CI]: 77%, 68%) and 79% (95% CI: 83%, 76%), respectively, versus 2% (95% CI: 17%, -15%) for placebo. The reductions in LDL-C were maintained until week 14 (6 weeks after the last dose). The trial also met the secondary endpoints, including significantly reducing PCSK9 levels by up to 94%. The 50mg and 90mg doses achieved reductions in PCSK9 levels of 89% (95% CI: 91%, 86%) and 94% (95% CI: 95%, 92%), respectively, versus 5% (95% CI: 23%, -18%) for placebo. The sustained reductions in PCSK9 levels were maintained until week 14 (6 weeks after last dose). Reducing PCSK9 levels leads to lower LDL-C levels in the bloodstream, which is known to reduce the risk of developing coronary heart disease. ION449 was generally well tolerated during the 12-week treatment period and the 12-week follow up period in the study.

Neutral

Ionis Pharmaceuticals, Inc. Presents at American College of Cardiology Annual Scientific Session & Expo, Apr-01-2022

2022-04-04 04:15:00

Ionis Pharmaceuticals, Inc. Presents at American College of Cardiology Annual Scientific Session & Expo, Apr-01-2022 . Venue: Washington, District Of Columbia, United States.

Neutral

Ionis Pharmaceuticals, Inc. Presents at Wells Fargo Annual Biotech Forum, Apr-12-2022

2022-03-29 20:00:00

Ionis Pharmaceuticals, Inc. Presents at Wells Fargo Annual Biotech Forum, Apr-12-2022 . Venue: Miami, Florida, United States. Speakers: Elizabeth L. Hougen, Executive VP of Finance & CFO, Jennifer Capuzelo, Director, Investor Relations.

Neutral

Wells Fargo Securities, LLC, Wells Fargo Annual Biotech Forum, Apr 12, 2022 through Apr 13, 2022

2022-03-29 11:02:00

Wells Fargo Securities, LLC, Wells Fargo Annual Biotech Forum, Apr 12, 2022 through Apr 13, 2022. Venue: Miami, Florida, United States.

Neutral

Ionis Pharmaceuticals, Inc. Presents at Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Day, Apr-01-2022 01:00 PM

2022-03-21 11:05:00

Ionis Pharmaceuticals, Inc. Presents at Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Day, Apr-01-2022 01:00 PM.

Neutral

Ionis Pharmaceuticals, Inc. Presents at Needham 21st Annual Healthcare Conference, Apr-11-2022 10:15 AM

2022-03-21 11:05:00

Ionis Pharmaceuticals, Inc. Presents at Needham 21st Annual Healthcare Conference, Apr-11-2022 10:15 AM.

Neutral

Ionis Pharmaceuticals, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2022 10:00 AM

2022-03-21 11:05:00

Ionis Pharmaceuticals, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2022 10:00 AM. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States. Speakers: Elizabeth L. Hougen, Executive VP of Finance & CFO.

Neutral

RBC Capital Markets, LLC, RBC Capital Markets Global Healthcare Conference, May 17, 2022 through May 18, 2022

2022-03-04 01:06:00

RBC Capital Markets, LLC, RBC Capital Markets Global Healthcare Conference, May 17, 2022 through May 18, 2022. Venue: InterContinental New York, Barclay hotel, New York, New York, United States.

Neutral

Guggenheim Securities, LLC, Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Day, Mar 31, 2022 through Apr 01, 2022

2022-02-24 12:30:00

Guggenheim Securities, LLC, Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Day, Mar 31, 2022 through Apr 01, 2022.

Neutral

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022

2022-02-17 10:42:00

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States.

Neutral

Needham & Company, LLC, Needham 21st Annual Healthcare Conference, Apr 11, 2022 through Apr 14, 2022

2022-02-11 23:04:00

Needham & Company, LLC, Needham 21st Annual Healthcare Conference, Apr 11, 2022 through Apr 14, 2022.

Neutral

Ionis Pharmaceuticals, Inc. Presents at SCOPE Summit 2022, Feb-09-2022 09:55 AM

2022-02-04 08:35:00

Ionis Pharmaceuticals, Inc. Presents at SCOPE Summit 2022, Feb-09-2022 09:55 AM. Venue: Orlanda, Florida, United States. Speakers: Eugene Schneider, Executive VP & Chief Clinical Development Officer.

Positive

Ionis Pharmaceuticals, Inc. Announce Discontinuation of Vupanorsen Clinical Development Program

2022-01-31 12:33:00

Pfizer Inc. and Ionis Pharmaceuticals, Inc. announced the discontinuation of the Pfizer-led clinical development program for vupanorsen (PF-07285557), an investigational antisense therapy that was being evaluated for potential indications in cardiovascular (CV) risk reduction and severe hypertriglyceridemia (SHTG). Pfizer made this decision after a thorough review of data from the global Phase 2b, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, 8-arm parallel-group study of vupanorsen in statin-treated participants with dyslipidemia — also known as TaRgeting ANGPTL3 with an aNtiSense oLigonucleotide in AdulTs with dyslipidEmia (TRANSLATE-TIMI 70). As previously announced, the study met its primary endpoint, achieving a statistically significant reduction in non-high density lipoprotein cholesterol (non-HDL-C), as well as statistically significant reductions in triglycerides (TG) and angiopoietin-like 3 (ANGPTL3). However, the magnitude of non-HDL-C and TG reduction observed did not support continuation of the clinical development program for CV risk reduction or SHTG. Vupanorsen was also associated with dose-dependent increases in liver fat, and higher doses were associated with elevations in the liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Pfizer will return development rights to vupanorsen to Ionis, from which it licensed the investigational therapy in a worldwide exclusive agreement in November 2019.

Positive

Pfizer and Ionis Pharmaceuticals, Inc Announce Discontinuation of Vupanorsen Clinical Development Program

2022-01-31 12:05:00

Pfizer Inc. and Ionis Pharmaceuticals, Inc. announced the discontinuation of the Pfizer-led clinical development program for vupanorsen (PF-07285557), an investigational antisense therapy that was being evaluated for potential indications in cardiovascular (CV) risk reduction and severe hypertriglyceridemia (SHTG). Pfizer made this decision after a thorough review of data from the global Phase 2b, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, 8-arm parallel-group study of vupanorsen in statin-treated participants with dyslipidemia — also known as TaRgeting ANGPTL3 with an aNtiSense oLigonucleotide in AdulTs with dyslipidEmia (TRANSLATE-TIMI 70). As previously announced, the study met its primary endpoint, achieving a statistically significant reduction in non-high density lipoprotein cholesterol (non-HDL-C), as well as statistically significant reductions in triglycerides (TG) and angiopoietin-like 3 (ANGPTL3). However, the magnitude of non-HDL-C and TG reduction observed did not support continuation of the clinical development program for CV risk reduction or SHTG. Vupanorsen was also associated with dose-dependent increases in liver fat, and higher doses were associated with elevations in the liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST).

Neutral

American College of Cardiology, Inc., American College of Cardiology Annual Scientific Session & Expo, Apr 01, 2022 through Apr 04, 2022

2022-01-26 12:00:00

American College of Cardiology, Inc., American College of Cardiology Annual Scientific Session & Expo, Apr 01, 2022 through Apr 04, 2022. Venue: Washington, District Of Columbia, United States.

Positive

Biogen Inc. Exercises Option with Ionis Pharmaceuticals, Inc. to Develop and Commercialize Investigational ASO for SMA

2022-01-04 12:34:00

Biogen Inc. and Ionis Pharmaceuticals, Inc. announced that Biogen exercised its option to obtain from Ionis a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB115/ION306. The companies have a broad strategic collaboration to develop novel therapies to treat neurological disorders. BIIB115 is an investigational antisense oligonucleotide in development for spinal muscular atrophy that may have the potential to help address additional unmet needs of patients as well as to be administered at extended dosing intervals. Biogen plans to advance BIIB115 to clinical trials to investigate safety, tolerability, pharmacokinetics, and efficacy. SMA is characterized by loss of motor neurons in the spinal cord and lower brain stem, resulting in severe and progressive muscular atrophy. People with SMA do not produce enough survival motor neuron protein, which is critical for the maintenance of motor neurons. BIIB115 is designed to target a root cause of SMA by increasing the production of functional SMN protein. As a part of the option exercise, Biogen made a one-time $60 million payment to Ionis in the fourth quarter of 2021. Future payments may include potential post-licensing development, regulatory and commercial milestone payments and royalties on annual worldwide net sales. Biogen will be solely responsible for the costs and expenses related to the development, manufacturing and potential future commercialization of BIIB115 following the option exercise. The SPINRAZA clinical development program encompasses 10 clinical studies, which have included more than 300 individuals across a broad spectrum of patient populations1, including two randomized controlled studies. The ongoing SHINE and NURTURE open-label extension studies are evaluating the long-term impact of SPINRAZA. The most common adverse events observed in clinical studies were respiratory infection, fever, constipation, headache, vomiting and back pain. Laboratory tests can monitor for renal toxicity and coagulation abnormalities, including acute severe low platelet counts, which have been observed after administration of some ASOs.

Positive

Ionis Pharmaceuticals, Inc. and Astrazeneca Close Deal to Develop and Commercialize Eplontersen

2021-12-29 07:00:00

Ionis Pharmaceuticals, Inc. announced the closing of the collaboration agreement with AstraZeneca to develop and commercialize eplontersen, Ionis' investigational antisense medicine for the treatment of transthyretin amyloidosis (ATTR), following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act). Eplontersen, formerly known as IONIS-TTR-LRx, is designed to reduce the production of transthyretin, or TTR protein, to treat ATTR, a systemic, progressive and fatal disease. It uses Ionis' advanced LIgand-Conjugated Antisense (LICA) technology.

Neutral

Drug Information Association, Inc., DIA Global Annual Meeting 2022, Jun 19, 2022 through Jun 23, 2022

2021-12-10 06:32:00

Drug Information Association, Inc., DIA Global Annual Meeting 2022, Jun 19, 2022 through Jun 23, 2022. Venue: Chicago, Illinois, United States.

Neutral

Ionis Pharmaceuticals, Inc. - Special Call

2021-12-07 07:00:00

To discuss the announcement related to strategic collaboration agreement with AstraZeneca to develop and commercialize eplontersen and related activities

Positive

AstraZeneca and Ionis Pharmaceuticals, Inc. to Collaborate on Eplontersen

2021-12-07 07:00:00

AstraZeneca has entered into a new global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. (Ionis) for eplontersen, formerly known as IONIS-TTR-LRX. Eplontersen is a ligand-conjugated antisense investigational medicine currently in Phase III clinical trials for amyloid transthyretin cardiomyopathy (ATTR-CM) and amyloid transthyretin polyneuropathy (ATTR-PN). It is designed to reduce the production of transthyretin (TTR protein) to treat both hereditary and non-hereditary forms of TTR amyloidosis (ATTR). The companies will jointly develop and commercialise eplontersen in the US, while AstraZeneca will develop and commercialise it in the rest of the world, except in Latin America. ATTR-CM is a systemic, progressive and fatal condition that leads to progressive heart failure and death within four years from diagnosis. It remains underdiagnosed and its prevalence is thought to be underestimated due to a lack of disease awareness and the heterogeneity of symptoms. Hereditary ATTR-PN is a debilitating disease that leads to peripheral nerve damage with motor disability within five years of diagnosis and, without treatment, is generally fatal within a decade. Hereditary ATTR-PN is expected to be the first indication for which the companies will seek regulatory approval for eplontersen, with the potential to file a new drug application with the US Food and Drug Administration by the end of 2022.

Neutral

Ionis Pharmaceuticals, Inc. - Analyst/Investor Day

2021-12-02 20:03:00

To provide an overview of its strategy, plans, and progress to bring its most advanced programs to market and achieve commercial success as well as highlight key technology advances

Negative

Ionis Pharmaceuticals, Inc. Announces Resignation of Peter N. Reikes as Member of the Board of Directors and Finance Committee of the Board

2021-11-26 21:06:00

On November 19, 2021, Peter N. Reikes, a member of the Board of Directors (‘Board’) and Finance Committee of the Board of Ionis Pharmaceuticals, Inc. (the ‘Company’), notified the Company that he is resigning from the Company’s Board effective November 21, 2021. Mr. Reikes has accepted a position with the U.S. Food and Drug Administration that requires him to step off the Company’s Board to avoid a perception of a conflict of interest.

Positive

Ionis Announces That Pfizer Reports Topline Results from Phase 2B Clinical Study of Vupanorsen

2021-11-24 11:30:00

Ionis Pharmaceuticals Inc. announced that Pfizer has provided an update on the Phase 2b study of vupanorsen, formerly IONIS-ANGPTL3-LRx. Vupanorsen is an investigational antisense therapy being developed for indications in cardiovascular (CV) risk reduction and severe hypertriglyceridemia (SHTG). In the dose-ranging study in subjects with elevated non-HDL-C and triglycerides (TG), the study met its primary endpoint, achieving a statistically significant reduction in non-HDL-C at all doses tested at 24 weeks, compared to placebo. In addition, subjects treated with vupanorsen achieved statistically significant reductions in TG and ANGPTL3 at all dose levels at 24 weeks, compared to placebo. The most common adverse events were injection site reactions, which occurred most often in the highest vupanorsen dose group. The most common laboratory abnormalities were increases in liver enzymes, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and were seen primarily at the higher doses. There were no Hy's Law cases in vupanorsen-treated subjects, and no meaningful changes in bilirubin. Certain doses of vupanorsen were associated with increases from baseline in hepatic fat fraction, measured by magnetic resonance imaging proton density fat fraction at Week 24, compared to placebo. No subject had a confirmed platelet count abnormality or a confirmed reduction in the estimated glomerular filtration rate. There were no serious adverse events (SAEs) related to treatment. The incidence of SAEs was similar between active and placebo groups. The global multicenter, double-blind, placebo-controlled, dose-ranging Phase 2b study TaRgeting ANGPTL3 with an aNtiSense oLigonucleotide in AdulTs with dyslipidEmia (TRANSLATE-TIMI 70) enrolled 286 participants (= 40 years old) with dyslipidemia, defined in this study as participants with elevated non-HDL-C (= 100 mg/dL) and TG (150-500 mg/dL), who are receiving a stable dose of a statin. Participants received either 80 mg, 120 mg or 160 mg every 4 weeks, or 60 mg, 80 mg, 120 mg or 160 mg every two weeks via subcutaneous injection. The study was designed to assess the efficacy, safety, tolerability and pharmacokinetics of vupanorsen, and the primary endpoint was percent change from baseline in non-HDL-C at week 24.

Positive

Ionis Pharmaceuticals, Inc. Initiates Phase 3 Clinical Program of Donidalorsen in Patients with Hereditary Angioedema

2021-11-18 18:30:00

Ionis Pharmaceuticals, Inc. announced initiation of OASIS-HAE, the registrational study in the donidalorsen (formerly IONIS-PKK-LRx) Phase 3 clinical program. Donidalorsen is an investigational antisense medicine designed to reduce the production of prekallikrein, which plays a key role in the activation of inflammatory mediators associated with acute attacks of hereditary angioedema (HAE). Donidalorsen uses Ionis' LIgand-Conjugated Antisense, or LICA, technology. OASIS-HAE is a double-blind, randomized, placebo-controlled registrational study in up to 84 patients with hereditary angioedema, Types 1 and 2. Patients will be randomized to receive monthly or bi-monthly subcutaneous donidalorsen for 25 weeks. Following the placebo-controlled portion of the study, patients may enter the 52-week open-label extension study. New Phase 2 data recently presented at ACAAI highlighted an overall reduction in moderate to severe attacks, and a reduction in these attacks starting with the second dose. For the final month of the study, all donidalorsen treated patients were attack-free. In this study, donidalorsen was safe and well tolerated.

Neutral

Ionis Pharmaceuticals, Inc. Presents at Access Insights Conference 2021, Nov-15-2021

2021-11-12 05:15:00

Ionis Pharmaceuticals, Inc. Presents at Access Insights Conference 2021, Nov-15-2021 . Speakers: Paul Voss, Executive Director, Market Access & Reimbursement.

Neutral

Ionis Pharmaceuticals, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov-30-2021 10:30 AM

2021-11-09 12:08:00

Ionis Pharmaceuticals, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov-30-2021 10:30 AM.

Neutral

Ionis Pharmaceuticals, Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-15-2021 10:40 AM

2021-11-09 12:08:00

Ionis Pharmaceuticals, Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-15-2021 10:40 AM. Venue: New York, New York, United States.

Positive

Ionis Pharmaceuticals, Inc. Announces That Positive Results from the Phase 2 Study of Its Investigational Antisense Medicine, Donidalorsen, Will Be Presented At the American College of Asthma, Allergy & Immunology

2021-11-07 12:05:00

Ionis Pharmaceuticals, Inc. announced that positive results from the Phase 2 study of its investigational antisense medicine, donidalorsen, will be presented at the American College of Asthma, Allergy & Immunology (ACAAI) Annual Scientific Meeting in New Orleans and via livestream, November 4-8. The Phase 2 study results support the clinical profile of donidalorsen as a potential, best-in-class prophylactic treatment for patients with hereditary angioedema (HAE), and underscore Ionis' commitment to advancing antisense technology to target the root cause of diseases. HAE is a rare and potentially fatal autosomal dominant disease that results in recurrent, painful attacks of swelling affecting the hands, feet, limbs, face, abdomen, larynx and trachea. Donidalorsen is an investigational antisense medicine designed to reduce the production of prekallikrein, which plays a key role in the activation of inflammatory mediators associated with acute attacks of HAE. Donidalorsen was developed using Ionis' advanced LIgand-Conjugated Antisense (LICA) technology. Topline results of the Phase 2 study, reported earlier this year, showed that donidalorsen met its primary and all secondary endpoints, achieving significant reductions in the number of attacks suffered by patients with hereditary angioedema (HAE) compared to placebo. These data support advancing donidalorsen into Phase 3 development, which Ionis plans to initiate this year.

Positive

Ionis Pharmaceuticals, Inc. Initiates Pivotal Phase 3 Clinical Study of Olezarsen in Patients with Severe Hypertriglyceridemia

2021-11-02 11:05:00

Ionis Pharmaceuticals, Inc. announced on November 2, 2021, the initiation of CORE, the second Phase 3 clinical study of olezarsen, formerly known as IONIS-APOCIII-LRx. The CORE study is evaluating olezarsen in people with severe hypertriglyceridemia (triglyceride levels = 500 mg/dL). Severe hypertriglyceridemia is a life-threatening condition associated with high levels of apoC-III and chylomicronemia, which lead to higher rates of acute pancreatitis, higher risk of cardiovascular disease, and has a high morbidity rate. Olezarsen is an investigational antisense medicine that uses Ionis' LIgand-Conjugated Antisense, or LICA, technology. It is designed to inhibit the production of apoC-III for patients who are at risk for cardiometabolic disease and acute pancreatitis due to elevated triglyceride levels. ApoC-III is a protein produced in the liver that regulates triglyceride metabolism in the blood. CORE is a global, double-blind, randomized, placebo-controlled, registrational, Phase 3 study in patients with severe hypertriglyceridemia. It is designed to compare olezarsen to placebo in patients with triglyceride levels equal to or greater than 500 mg/dL who are on the current available standard of care therapies for elevated triglycerides. The primary endpoint of the study is the percent change in fasting triglycerides from baseline at month 6. Secondary endpoints include: percent change from baseline in triglycerides at month 12; proportion of patients who achieve fasting triglycerides less than 500 mg/dL, 880mg/dL and/or 1,000 mg/dL and percent change from baseline in other atherogenic lipids at months 6 and 12; and adjudicated acute pancreatitis event rates. In a Phase 2 clinical study, results showed that olezarsen met its primary and key secondary endpoints with significant reductions in triglyceride and apoC-III levels, and a favorable safety and tolerability profile in the treatment of patients with hypertriglyceridemia (=200 to =500 mg/dL) who have established cardiovascular disease or are at risk for cardiovascular disease. In addition, 91% of subjects achieved a normal triglyceride level of <150 mg/dL. The broad olezarsen development program aims to enhance the full profile of olezarsen and enroll more than 1,500 patients. CORE is one of several clinical studies aimed at evaluating olezarsen's potential to treat diseases caused by high triglycerides. BALANCE, a Phase 3 clinical study evaluating olezarsen in people with familial chylomicronemia syndrome or FCS, is on track for a data readout in 2023.

Neutral

Ionis Pharmaceuticals, Inc., Q3 2021 Earnings Call, Nov 03, 2021

2021-10-20 11:05:00

Ionis Pharmaceuticals, Inc., Q3 2021 Earnings Call, Nov 03, 2021

Neutral

Informa plc, TIDES EUROPE: Oligonucleotide & Peptide Therapeutics, Nov 15, 2021 through Nov 17, 2021

2021-10-12 20:23:00

Informa plc, TIDES EUROPE: Oligonucleotide & Peptide Therapeutics, Nov 15, 2021 through Nov 17, 2021.

Neutral

Ionis Pharmaceuticals, Inc. Presents at TIDES EUROPE: Oligonucleotide & Peptide Therapeutics, Nov-15-2021 through Nov-17-2021

2021-10-12 20:23:00

Ionis Pharmaceuticals, Inc. Presents at TIDES EUROPE: Oligonucleotide & Peptide Therapeutics, Nov-15-2021 through Nov-17-2021. Presentation Date & Speakers: Nov-16-2021, Gustavo Buchele, Executive Director, Clinical Development, Michela Brambatti, Associate Director, Clinical Development. Nov-17-2021, Jennifer Franklin, Executive Director, CMC Regulatory Affairs.

Neutral

Ionis Pharmaceuticals, Inc. Presents at 2nd Dry AMD Therapeutic Development Summit, Oct-19-2021

2021-10-12 18:27:00

Ionis Pharmaceuticals, Inc. Presents at 2nd Dry AMD Therapeutic Development Summit, Oct-19-2021 . Speakers: Michael McCaleb, Vice President, Clinical Development, & Head of Ophthalmology Disease Franchise.

Neutral

Hanson Wade Limited, 2nd Dry AMD Therapeutic Development Summit, Oct 19, 2021 through Oct 21, 2021

2021-10-12 06:27:00

Hanson Wade Limited, 2nd Dry AMD Therapeutic Development Summit, Oct 19, 2021 through Oct 21, 2021.

Neutral

Ionis Pharmaceuticals, Inc. Presents at International Oligonucleotide and Peptide Conference, Oct-19-2021 04:55 PM

2021-09-30 20:47:00

Ionis Pharmaceuticals, Inc. Presents at International Oligonucleotide and Peptide Conference, Oct-19-2021 04:55 PM. Speakers: Richard S. Geary, Executive VP & Chief Development Officer.

Neutral

Tekno Scienze S.R.L., International Oligonucleotide and Peptide Conference, Oct 18, 2021 through Oct 19, 2021

2021-09-30 20:01:00

Tekno Scienze S.R.L., International Oligonucleotide and Peptide Conference, Oct 18, 2021 through Oct 19, 2021.

Neutral

Ionis Pharmaceuticals, Inc. Presents at Longwood Healthcare Leaders Conference, Oct-05-2021 01:30 PM

2021-09-28 18:44:00

Ionis Pharmaceuticals, Inc. Presents at Longwood Healthcare Leaders Conference, Oct-05-2021 01:30 PM. Speakers: Brett P. Monia, Founder, CEO & Director.

Neutral

Longwood Fund, Longwood Healthcare Leaders Conference, Oct 04, 2021 through Oct 05, 2021

2021-09-28 13:09:00

Longwood Fund, Longwood Healthcare Leaders Conference, Oct 04, 2021 through Oct 05, 2021.

Neutral

Ionis Pharmaceuticals, Inc. Presents at 17th Annual Meeting of the Oligonucleotide Therapeutics Society, Sep-26-2021

2021-09-24 16:33:00

Ionis Pharmaceuticals, Inc. Presents at 17th Annual Meeting of the Oligonucleotide Therapeutics Society, Sep-26-2021 . Speakers: Holly Kordasiewicz, Executive Director of Neurological Drug Discovery, Kenneth Newman, Vice President of Clinical Development, Richard S. Geary, Executive VP & Chief Development Officer.

Neutral

Ionis Pharmaceuticals, Inc. Presents at Second Annual Undruggable Leaders Forum, Sep-15-2021 04:20 PM

2021-09-15 16:12:00

Ionis Pharmaceuticals, Inc. Presents at Second Annual Undruggable Leaders Forum, Sep-15-2021 04:20 PM. Speakers: Shuling Guo, Vice President, Antisense Drug Discovery.

Neutral

GreyGreen, Second Annual Undruggable Leaders Forum, Sep 15, 2021 through Sep 16, 2021

2021-09-15 11:32:00

GreyGreen, Second Annual Undruggable Leaders Forum, Sep 15, 2021 through Sep 16, 2021.

Positive

Flamingo Therapeutics, Inc. Expands Alliance with Ionis Pharmaceuticals to Develop RNA-Targeted Therapies for Oncology

2021-09-09 12:00:00

Flamingo Therapeutics, Inc. announced that it has entered into an agreement with Ionis Pharmaceuticals to develop RNA-targeted therapies to treat various forms of cancer. This alliance is an expansion of an existing collaboration with Ionis on the FLAME™ discovery engine. The agreement and discovery alliance will leverage Flamingo's deep expertise in oncology and long non-coding RNAs (lncRNAs) in combination with Ionis' expertise in RNA-targeted drug discovery and development to advance candidates against targets considered undruggable with traditional approaches. Flamingo's pipeline will include three clinical-stage programs from Ionis, inhibitors of STAT-3, Androgen Receptor (AR) and IRF4, and one preclinical-stage program that targets MALAT1, a well-characterized lncRNA target. Flamingo will also advance its proprietary discovery engine, FLAME (Flamingo LncRNA Antisense Mining Engine), that addresses lncRNAs, a large and untapped class of disease-causing targets within the dark matter of the human genome. Under the terms of the agreement, Ionis is eligible to receive milestone payments and royalties on future product sales of the STAT3, AR, IRF4 and MALAT1 programs. Flamingo retains full rights to its FLAME platform and all lncRNA programs outside of MALAT1.

Neutral

OLIGONUCLEOTIDE THERAPEUTICS SOCIETY INC, 17th Annual Meeting of the Oligonucleotide Therapeutics Society, Sep 26, 2021 through Sep 29, 2021

2021-09-04 15:00:00

OLIGONUCLEOTIDE THERAPEUTICS SOCIETY INC, 17th Annual Meeting of the Oligonucleotide Therapeutics Society, Sep 26, 2021 through Sep 29, 2021.

Neutral

Cambridge Innovation Institute, LLC, SCOPE Summit 2022, Feb 07, 2022 through Feb 10, 2022

2021-09-04 12:00:00

Cambridge Innovation Institute, LLC, SCOPE Summit 2022, Feb 07, 2022 through Feb 10, 2022. Venue: Orlanda, Florida, United States.

Neutral

Ionis Pharmaceuticals, Inc., 3rd European ATTR Amyloidosis meeting, Sep 06, 2021 through Sep 08, 2021

2021-09-03 11:34:00

Ionis Pharmaceuticals, Inc., 3rd European ATTR Amyloidosis meeting, Sep 06, 2021 through Sep 08, 2021.

Neutral

Ionis Pharmaceuticals, Inc., 3rd European ATTR Amyloidosis meeting, Sep 06, 2021 through Sep 08, 2021

2021-09-03 11:34:00

Ionis Pharmaceuticals, Inc., 3rd European ATTR Amyloidosis meeting, Sep 06, 2021 through Sep 08, 2021.

Neutral

Ionis Pharmaceuticals, Inc. Presents at 3rd European ATTR Amyloidosis meeting, Sep-06-2021 through Sep-08-2021

2021-09-03 11:34:00

Ionis Pharmaceuticals, Inc. Presents at 3rd European ATTR Amyloidosis meeting, Sep-06-2021 through Sep-08-2021. Presentation Date & Speakers: Sep-07-2021, Gustavo Buchele, M.D., Ph.D., executive director, clinical development. Sep-08-2021, Sotirios Tsimikas, M.D., senior vice president, clinical development and cardiovascular franchise leader.

Neutral

Ionis Pharmaceuticals, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-13-2021 02:00 PM

2021-09-02 11:05:00

Ionis Pharmaceuticals, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-13-2021 02:00 PM. Venue: New Windsor, United States.

Neutral

Ionis Pharmaceuticals, Inc. Presents at Bank of America Global Healthcare Conference, Sep-15-2021 10:55 AM

2021-09-02 11:05:00

Ionis Pharmaceuticals, Inc. Presents at Bank of America Global Healthcare Conference, Sep-15-2021 10:55 AM. Speakers: Elizabeth L. Hougen, Executive VP of Finance & CFO.

Neutral

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021

2021-08-24 20:29:00

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.

Neutral

Ionis Pharmaceuticals, Inc. Presents at World Orphan Drug Congress USA 2021, Aug-27-2021 03:20 PM

2021-08-20 20:24:00

Ionis Pharmaceuticals, Inc. Presents at World Orphan Drug Congress USA 2021, Aug-27-2021 03:20 PM. Venue: Gaylord National Resort & Convention Center, Oxon Hill, Maryland, United States. Speakers: Amy Shea, Director, Diagnostics & Strategic Initiatives.

Neutral

Terrapinn Holdings Ltd, World Orphan Drug Congress USA 2021, Aug 25, 2021 through Aug 27, 2021

2021-08-20 17:31:00

Terrapinn Holdings Ltd, World Orphan Drug Congress USA 2021, Aug 25, 2021 through Aug 27, 2021. Venue: Gaylord National Resort & Convention Center, Oxon Hill, Maryland, United States.

Neutral

Ionis Pharmaceuticals, Inc. Presents at 5th Annual IPF Summit, Aug-26-2021 04:00 PM

2021-08-10 14:19:00

Ionis Pharmaceuticals, Inc. Presents at 5th Annual IPF Summit, Aug-26-2021 04:00 PM. Speakers: Jeff Crosby, Director of Pulmonary Drug Discovery.

Neutral

Hanson Wade Limited, 5th Annual IPF Summit, Aug 25, 2021 through Aug 27, 2021

2021-08-10 12:54:00

Hanson Wade Limited, 5th Annual IPF Summit, Aug 25, 2021 through Aug 27, 2021.

Neutral

Ionis Pharmaceuticals, Inc. has filed a Shelf Registration in the amount of $253.327 million.

2021-08-05 00:00:00

Ionis Pharmaceuticals, Inc. has filed a Shelf Registration in the amount of $253.327 million. Security Name: Common Stock Securities Offered: 6,700,000 Transaction Features: ESOP Related Offering

Negative

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2021

2021-08-04 15:16:00

Ionis Pharmaceuticals, Inc. provided earnings guidance for the full year 2021. For the year, the company on track to achieve revenue of $600 million being unchanged. Net loss is expected to be $110 million compared to $75 million forecasted previously.

Positive

Ionis Pharmaceuticals, Inc. Continues to Advance in the Clinic as the Potential First-In-Class Treatment for Lipoprotein(a) or Lp(a)-Driven Cardiovascular Disease

2021-08-02 13:30:00

Ionis Pharmaceuticals, Inc. announced that pelacarsen, formerly known as AKCEA-APO(a)-LRx, and licensed by Novartis for exclusive worldwide development and commercialization, continues to advance in the clinic as the potential first-in-class treatment for lipoprotein(a) or Lp(a)-driven cardiovascular disease. The Novartis pivotal Phase 3 cardiovascular outcomes study of pelacarsen, Lp(a) HORIZON (NCT04023552), has reached 50% enrollment with a target goal of 7,680 trial participants. Pelacarsen is an investigational antisense medicine that uses Ionis' proprietary Ligand Conjugated Antisense (LICA) technology platform. It is designed to inhibit the production of apolipoprotein(a) in the liver to target elevated Lp(a) levels, an independent genetic risk factor for cardiovascular diseases (CVD), that are determined at birth and cannot be controlled with diet or exercise. High Lp(a) levels are associated with significant risk of cardiovascular disease, including heart attacks and strokes. There are no approved pharmacological therapies to effectively lower Lp(a). Data from a Phase 2 study published in the New England Journal of Medicine showed pelacarsen provided potent dose-dependent reductions of Lp(a) compared to placebo, with a favorable safety and tolerability profile in patients who had elevated Lp(a) levels and established CVD. These data support the potential of antisense-mediated reduction of Lp(a) with pelacarsen. Ionis earned a $25 million milestone payment from Novartis for achieving 50% enrollment in the pivotal Phase 3 study. In 2017, Novartis entered a collaboration agreement with Ionis for pelacarsen. In February 2019, Novartis exercised an option to license the rights to develop and commercialize pelacarsen for targeted cardiovascular therapy for $150 million. Under the terms of the agreement, Novartis is exclusively responsible for worldwide development and commercialization of pelacarsen and Ionis is eligible to receive up to $675 million in regulatory and sales milestones. Ionis is also eligible to receive tiered royalties in the mid-teens to low 20% range on net sales of pelacarsen.

Positive

Ionis Pharmaceuticals, Inc. Completes Enrollment in Pivotal NEURO-TTRansform Study of Eplontersen

2021-07-29 11:05:00

Ionis Pharmaceuticals, Inc. announced it has completed enrollment of NEURO-TTRansform, the company's Phase 3 study of eplontersen, formerly AKCEA-TTR-LRx, for people with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN). The company has exceeded the enrollment target in NEURO-TTRansform and expects to register more than 160 patients in the study. Eplontersen is an investigational antisense medicine designed to inhibit production of transthyretin (TTR), a protein that forms the amyloid deposits that cause debilitating nerve damage throughout the body. Eplontersen utilizes Ionis' advanced LIgand Conjugated Antisense technology. In a Phase 1 clinical trial, patients treated with eplontersen experienced reductions in TTR of up to 94%. Ionis is also studying eplontersen in the CARDIO-TTRansform Phase 3 study in patients with hereditary and wild-type cardiomyopathy (ATTR-CM).

Positive

Biogen Inc. and Ionis Pharmaceuticals, Inc. Announces Positive Topline Clinical Data on Investigational Alzheimer's Disease Treatment at AAIC

2021-07-26 20:35:00

Biogen Inc. and Ionis Pharmaceuticals, Inc. announced that topline data from a Phase 1b placebo-controlled, multiple ascending dose clinical study showed that BIIB080/IONIS-MAPTRx met its primary objective of safety and tolerability in patients with mild Alzheimer's disease. The study demonstrated robust time and dose dependent lowering of tau protein in cerebrospinal fluid (CSF) over the three-month treatment period and sustained reductions during the six-month post-treatment period. In patients receiving BIIB080, there were dose-dependent decreases in the concentration of total-tau in CSF eight weeks post-last dose (Day 141) with a mean percentage reduction of 30 percent, 40 percent and 49 percent in the low, medium and high dose groups treated every four-weeks, respectively, and 42 percent in the group treated every 12 weeks. Total-tau in the CSF continued to decline 16 weeks post-last dose in patients treated with BIIB080 in the high dose four-week and 12-week dose groups, showing a 55 percent and 49 percent mean reduction from baseline, respectively. CSF was not collected 16 weeks post-last dose in the low and medium four-week dose groups. There were similar dose-dependent decreases in the levels of phosphorylated tau. All participants (n=46) completed the Multiple Ascending Dose (MAD) period and 43 participants completed the Post-Treatment (PT) period (3 participants voluntarily withdrew). These data were presented in a poster session at the 2021 Alzheimer's Association International Conference (AAIC) held virtually and in Denver, Colo., July 26 – 30. Alzheimer's disease is a progressive neurodegenerative disorder characterized by cognitive and functional decline resulting in significant disability. Until recently, treatment was limited to management of symptoms. BIIB080 is an investigational antisense therapy designed to target microtubule-associated protein tau (MAPT) mRNA and prevent production of tau protein. Growing evidence suggests that aggregated, hype phosphorylated tau may be a key driver of neurodegeneration in Alzheimer's disease as well as other tauopathies including progressive supranuclear palsy and frontotemporal degeneration. In preclinical studies in MAPT transgenic mice, MAPT-targeted antisense treatment demonstrated robust tau-lowering in CNS tissues and prevention and reversal of disease. The primary objective of the Phase 1b first-in-human study was to assess safety and tolerability of multiple intrathecal (IT) bolus administrations of BIIB080. The study was divided into two parts: Part 1, a MAD study of 46 patients with mild Alzheimer's disease comprising a three-month Treatment Evaluation Period and a six-month PT period; Part 2, an open label long-term extension study comprising a 12-month Treatment Evaluation Period and a four- or six-month PT period. Four ascending dose cohorts were enrolled sequentially and randomized 3:1 to IT bolus administrations of BIIB080 or placebo. Patients aged 50-74 years with mild Alzheimer's disease and confirmed amyloid positivity (via CSF) at screening were considered eligible. Part 1 is now complete; Part 2 is currently ongoing (EudraCT: 2016-002713-22; NCT03186989). The characteristics of patients at baseline were representative of relatively younger, mild Alzheimer's disease patients and were generally similar across trial groups. All adverse events were mild to moderate in severity with no serious adverse events occurring in any patients that received BIIB080. There were no deaths, dose-limiting adverse events or dosing discontinuations.

Neutral

Ionis Pharmaceuticals, Inc. Presents at Wells Fargo 2021 Virtual Healthcare Conference, Sep-10-2021 02:00 PM

2021-07-22 14:24:00

Ionis Pharmaceuticals, Inc. Presents at Wells Fargo 2021 Virtual Healthcare Conference, Sep-10-2021 02:00 PM. Speakers: Brett P. Monia, Founder, CEO & Director, Onaiza Cadoret-Manier, Executive VP and Chief Corporate Development & Commercial Officer.

Neutral

Wells Fargo Securities, LLC, Wells Fargo 2021 Virtual Healthcare Conference, Sep 09, 2021 through Sep 10, 2021

2021-07-22 09:08:00

Wells Fargo Securities, LLC, Wells Fargo 2021 Virtual Healthcare Conference, Sep 09, 2021 through Sep 10, 2021.

Neutral

Ionis Pharmaceuticals, Inc., Q2 2021 Earnings Call, Aug 04, 2021

2021-07-21 11:05:00

Ionis Pharmaceuticals, Inc., Q2 2021 Earnings Call, Aug 04, 2021

Neutral

BicycleTx Limited and Ionis Pharmaceuticals, Inc. Enters into A Collaboration and License Agreement

2021-07-13 11:54:00

On July 9, 2021, BicycleTx Limited and Ionis Pharmaceuticals, Inc. entered into a collaboration and license agreement (the “Collaboration Agreement”). The parties entered into the Collaboration Agreement following the exercise on July 9, 2021 by Ionis of the exclusive option (the “Option”) granted by BTx to Ionis pursuant to an Evaluation and Option Agreement dated December 31, 2020, between the Company, BTx and Ionis (the “Option Agreement”). Pursuant to the Collaboration Agreement, BTx granted to Ionis a worldwide exclusive license under BTx’s relevant technology to research, develop, manufacture and commercialize products incorporating Bicycle peptides directed to the protein coded by the gene TFRC1 (transferrin receptor) (“TfR1 Bicycles”) intended for the delivery of oligonucleotide compounds directed to targets selected by Ionis for diagnostic, therapeutic, prophylactic and preventative uses in humans. Each party will be responsible for optimization of such TfR1 Bicycles and other research and discovery activities related to TfR1 Bicycles, and thereafter Ionis will be responsible for all future research, development, manufacture and commercialization activities. Bicycle has retained certain rights, including the right to use TfR1 Bicycles for all non-oligonucleotide therapeutic purposes. Under the Collaboration Agreement, Ionis will make an upfront payment to BTx of $31.0 million and will make an equity investment in the Company of $11.0 million. Ionis also previously paid a $3.0 million option fee under the Option Agreement to obtain the Option. On a collaboration target-by-collaboration target basis, Ionis will be required to make a payment to BTx of a low-single-digit million dollar amount upon acceptance of an investigational new drug application for the first product directed to such collaboration target (provided that Ionis will have a credit of a high single-digit million dollar amount to be applied towards the IND acceptance fee for four collaboration targets), and Ionis will be required to make milestone payments to BTx upon the achievement of specified development and regulatory milestones of up to a low double-digit million dollar amount per collaboration target. In addition, BTx is also eligible to receive up to a low double-digit million dollar amount in cumulative sales milestone payments. BTx is entitled to receive tiered royalty payments on net sales at percentages in the low single digits, subject to certain standard reductions and offsets. Royalties will be payable, on a product-by-product and country-by-country basis, until the latest of the expiration of specified licensed patents covering such product in such country, ten years from first commercial sale of such product in such country, or expiration of marketing exclusivity for such product in such country.

Neutral

Ionis Enters Exclusive Licensing Agreement with Bicycle Therapeutics Aimed at Further Advancing LICA Technology

2021-07-13 10:59:00

Ionis Pharmaceuticals, Inc. announced that it has entered into an exclusive licensing agreement with Bicycle Therapeutics plc to increase the delivery capabilities of Ionis' advanced LIgand Conjugated Antisense (LICA) medicines. The agreement provides Ionis exclusive access to Bicycle's proprietary macrocyclic peptides, referred to as Bicycles, to design LICAs that target transferrin receptor 1 for use with oligonucleotides. This LICA strategy has demonstrated both the improved delivery of antisense medicines to muscle tissue, including cardiac muscle, as well as the potential to cross the blood brain barrier. Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines, Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Under terms of the agreement, Ionis obtained an exclusive license to Bicycle's technology covering the entire class of transferrin receptor 1 Bicycles for use in targeted delivery of oligonucleotide drugs. Ionis made a $45 million upfront payment to Bicycle which included a license fee, an option fee, and an $11 million equity investment in Bicycle. Bicycle will be eligible to earn development and regulatory milestone payments on a program-by-program basis and royalties on product sales.

Neutral

Bicycle Therapeutics Enters Exclusive License and Collaboration Agreement with Ionis to Develop Targeted Oligonucleotide Therapeutics

2021-07-13 10:59:00

Bicycle Therapeutics plc announced that Ionis Pharmaceuticals has exercised its option and entered into an exclusive worldwide license and collaboration agreement for tissue-targeted delivery of oligonucleotide therapeutics using Bicycles with high affinity to the transferrin receptor (TfR1). Ionis had an option for an exclusive license under the terms of a December 2020 evaluation and option agreement. The agreement granted Ionis the right to evaluate tissue-targeting TfR1 binding Bicycles as vehicles to deliver oligonucleotide therapeutics to specific organ systems and an option to obtain an exclusive license at the end of the evaluation period. Bicycle receives a total of $45 million upfront, which includes a license fee, an option fee, and an $11 million equity investment. Bicycle is also eligible to receive development, regulatory and commercial milestone payments and royalties for each program developed under the collaboration. Bicycle has identified binders that it believes to be the first small molecules to target TfR1 with high specificity without modifying TfR1’s natural function. These binders present broad conjugation potential across multiple payloads, thereby resulting in the potential to treat diseases in multiple therapeutic areas, including those of the skeletal and cardiac muscles and of the central nervous system. Bicycle is currently also collaborating with the Dementia Discovery Fund (DDF) to advance potential TfR1 Bicycles for treating dementia. Under the terms of the license and collaboration agreement, Ionis and Bicycle will collaborate to develop a pipeline of oligonucleotide therapeutic product candidates delivered using the tissue-targeting TfR1 Bicycle technology, while Bicycle retains the rights to use TfR1 Bicycles for all non-oligonucleotide therapeutic purposes, including within its existing collaboration with DDF targeting dementia.

Positive

Bicycle Therapeutics plc announced that it expects to receive $10.999966 million in funding from Ionis Pharmaceuticals, Inc.

2021-07-09 00:00:00

Bicycle Therapeutics plc announced that it has entered into a share purchase agreement with new investor Ionis Pharmaceuticals, Inc. for private placement of 282,485 common shares at a price of $38.94 per share for gross proceeds of $10,999,966 on July 9, 2021. The shares are subject to standstill restrictions expiring on 18-month anniversary of the agreement. The investor will not sell any of shares until the earlier of he first anniversary of the closing of agreement and the termination of the collaboration agreement. The shares will be issued pursuant to exemption provided in Section 4(a)(2) of the Securities Act.

Neutral

Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021

2021-07-08 08:44:00

Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021. Venue: New York, New York, United States.

Fundamental Summary

Ionis Pharmaceuticals released impressive Q1 results on 2022-05-04. Their growth and income factors performance indicate that company management is focused on the right targets and executing well. There should be significant upside potential for the stock looking forward. As such, Ionis Pharmaceuticals received an overall score of 79 and a BUY recommendation.

Ionis Pharmaceuticals reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 142 million compared to USD 112 million a year ago. Net loss was USD 65 million compared to USD 90 million a year ago. Basic loss per share from continuing operations was USD 0.46 compared to USD 0.64 a year ago. Diluted loss per share from continuing operations was USD 0.46 compared to USD 0.64 a year ago.

Business Description

Ionis Pharmaceuticals discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals was founded in 1989 and is based in Carlsbad, California.

Sector Overview

Ionis Pharmaceuticals is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Ionis Pharmaceuticals's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 2,519.1 -3.5% 68
Liabilities 1,809.5 -1.7% 59
Price to Book 7.7 37.7% 67
Cash & Equivalents 542.5 -37.6% 43
Equity 709.6 -8.1% 58
EBITDA 45.3 168.4% 94
Total Revenues 840.8 3.7% 62
Parameter Value Change Score
Return on Equity -0.6 85.2% 53
Net Cashflow 128.4 -72.8% 88
Capital Expenditure -12.9 -7.8% 60
Asset Turnover 0.4 8.8% 86
Free Cashflow 0.3 173.9% 96

* All values are TTM

The below chart reflects Ionis Pharmaceuticals's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Ionis Pharmaceuticals's peer average final assessment score stands on 66.0, Ionis Pharmaceuticals's score is 79.

  •  IONS
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Amgen Inc. 130.1B 69 78 81
Hold
77
77 0 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 1 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 3 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 4 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 5 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 7 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 8 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 9 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 10 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 11 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 12 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 13 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 14 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 15 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 16 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 17 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 18 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 19 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 20 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 21 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 22 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 23 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 25 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 27 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 28 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 29 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 30 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 31 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 32 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 33 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 35 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 36 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 37 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 38 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 39 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 40 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 41 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 42 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 43 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 45 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 46 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 47 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 48 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 49 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 50 1
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 51 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 52 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 53 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 54 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 55 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 56 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 57 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 58 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 59 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 60 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 61 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 62 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 63 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 64 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 65 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 66 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 67 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 68 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 69 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 70 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 73 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 74 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 75 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 77 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 78 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 79 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 80 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 81 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 82 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 83 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 84 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 85 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 86 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 87 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 88 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 89 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 90 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 91 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 92 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 93 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 94 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Ionis Pharmaceuticals's stock is now priced above its 50-day and 200-day, but below its 5-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in the medium and long-term. In particular, many institutional investors keep close watch of the 200-day moving average. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Ionis Pharmaceuticals's stock doesn't strongly signal being overbought or oversold. Overall, these technical indicators don't clearly signal directional momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 68.

Neutral 68
Close Price 37.97
52W Low 25.61
52W High 43.0
5D MA 38.56
50D MA 37.37
200D MA 34.05
MACD 0.43
RSI 40.99
STOCH 76.54

Balance Sheet Analysis

Two metrics jump up as the most significant positive drivers of the balance sheet strength in Ionis Pharmaceuticalss recent report: Assets and Book Value Factors. Ionis Pharmaceuticals's management was effective in managing the value of the assets on their balance sheet, which now sits at 2519.1 and represents a -3.5% change from the previous report. These results, specifically in contrast to their industry peers' performance, should support an upswing in the company's stock price. Consequently, their asset movement received a grade of 68. Also, Ionis Pharmaceuticals publishes solid book value factor metrics in this report. Price to book ratio (P/B) now sits at 7.7 and represents a 37.7% change from the previous report. The company's book value factor metrics are even more remarkable when compared to their peers. Therefore, its book value factors earned a score of 67. That said, one metric, Cash & Equivalents, stood out as strongly negative. Ionis Pharmaceuticals's management did a relatively poor job managing cash and cash equivalents, which now sit at 542.5 and represents a -37.6% change from the last reporting period. The company's cash and cash equivalents metrics highlight a difficult overall financial situation, which may, unfortunately, continue moving forward unless management makes significant changes. Consequently, their cash and cash equivalents movement received a grade of 43. Therefore, it received a score of 62.

Parameter Value Change Score
Assets 2,519.1 -3.5% 68
Liabilities 1,809.5 -1.7% 59
Price to Book 7.7 37.7% 67
Cash & Equivalents 542.5 -37.6% 43
Equity 709.6 -8.1% 58
* All values are TTM

The below chart describes Ionis Pharmaceuticals's performance as reflected on its balance sheet with respect to its peers. While Ionis Pharmaceuticals received a balance sheet score of 62, the average of its peers stands on 64.0.

  •  IONS
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Amgen Inc. 130.1B 72 68 86 53 62 69 0 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 1 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 3 1
BioNTech SE 34.0B 75 69 64 97 73 75 4 1
Seagen Inc. 32.9B 59 68 55 43 66 61 5 1
Biogen Inc. 29.7B 57 72 92 50 76 76 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 7 1
Incyte Corporation 16.8B 71 72 95 82 79 83 8 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 9 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 10 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 11 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 12 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 13 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 14 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 15 1
Alkermes plc 5.0B 63 66 46 54 71 62 16 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 17 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 18 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 19 1
Natera, Inc. 3.6B 73 65 43 95 42 54 20 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 21 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 22 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 23 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 25 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 27 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 28 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 29 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 30 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 31 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 32 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 33 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 35 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 36 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 37 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 38 1
Geron Corporation 566.2M 69 72 37 59 62 60 39 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 40 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 41 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 42 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 43 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 45 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 46 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 47 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 48 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 49 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 50 1
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 51 1
CureVac N.V. 2.6B 49 64 75 52 52 57 52 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 53 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 54 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 55 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 56 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 57 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 58 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 59 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 60 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 61 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 62 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 63 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 64 1
CareDx, Inc 1.2B 54 67 52 39 51 52 65 1
Vericel Corporation 1.1B 51 65 56 53 61 57 66 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 67 1
MannKind Corporation 957.2M 79 59 50 40 64 57 68 1
Merus N.V. 941.6M 59 68 50 83 81 70 69 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 70 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 73 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 74 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 75 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 76 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 77 1
Immatics N.V. 538.7M 56 70 84 95 73 76 78 1
Agenus Inc. 520.5M 73 62 37 55 60 54 79 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 80 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 81 1
Affimed N.V. 415.0M 56 66 63 56 47 54 82 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 83 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 84 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 85 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 86 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 87 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 88 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 89 1
AC Immune SA 299.8M 84 64 47 53 75 68 90 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 91 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 92 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 93 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 94 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

Ionis Pharmaceuticals's income statement showed strong financials, specifically EBITDA and Revenue Efficiency. Ionis Pharmaceuticals reported impressive EBITDA this period. At filing, EBITDA was reported as 45.3, representing 168.4% change from the previous period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 24.4%. Their EBITDA metrics are even more impressive relative to their peers and competitors, and its likely the stock price has room to grow to reflect its intrinsic value accurately. Therefore, its EBITDA component earned a score of 94. Also, Ionis Pharmaceuticals reported highly encouraging numbers for its revenue efficiency. This characteristic can affect companies in the same industry and market capitalization by up to 13.1%. Their revenue efficiency, specifically in contrast to their industry peers', should support a positive movement in the company's stock price. Consequently, their revenue efficiency received a grade of 62. On the other hand, Return Factors, jumped out as looking problematic. Ionis Pharmaceuticals's reported return on equity (ROE) ratio was -0.6, representing a change of 85.2%. This metric might have a 3.6 percent impact on companies in the same industry and with the same market capitalization. They does not yet appear to be headed in the right direction regarding these return on equity and return on assets metrics. Therefore, their return factors component earned a score of 53. Consequently, the companie's income statement earned a rank of 86.

Parameter Value Change Score
EBITDA 45.3 168.4% 94
Total Revenues 840.8 3.7% 62
Return on Equity -0.6 85.2% 53
* All values are TTM

The below chart describes Ionis Pharmaceuticals's performance as reflected on its income statement with respect to its peers. While Ionis Pharmaceuticals received a income statement score of 86 , the average of its peers stands on 69.0.

  •  IONS
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Amgen Inc. 130.1B 74 75 64 78 0 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 1 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 3 1
BioNTech SE 34.0B 41 89 75 79 4 1
Seagen Inc. 32.9B 54 65 70 62 5 1
Biogen Inc. 29.7B 90 57 73 70 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 7 1
Incyte Corporation 16.8B 59 77 60 73 8 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 9 1
United Therapeutics Corporation 10.6B 57 91 54 82 10 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 11 1
Exelixis, Inc. 6.7B 54 91 54 81 12 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 13 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 14 1
Ascendis Pharma A/S 5.2B 38 68 46 54 15 1
Alkermes plc 5.0B 69 55 81 62 16 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 17 1
Novavax, Inc. 4.0B 41 89 54 75 18 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 19 1
Natera, Inc. 3.6B 52 51 78 52 20 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 21 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 22 1
Insmed Incorporated 2.4B 51 58 73 57 23 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 25 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 27 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 28 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 29 1
IVERIC bio, Inc. 1.1B 84 58 79 70 30 1
FibroGen, Inc. 1.0B 48 74 63 67 31 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 32 1
ImmunoGen, Inc. 946.1M 40 73 71 64 33 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 35 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 36 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 37 1
AnaptysBio, Inc. 586.3M 97 50 77 68 38 1
Geron Corporation 566.2M 89 67 73 78 39 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 40 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 41 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 42 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 43 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 45 1
Precigen, Inc. 299.1M 57 87 59 79 46 1
bluebird bio, Inc. 288.7M 99 91 61 96 47 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 48 1
MacroGenics, Inc. 184.6M 95 56 74 71 49 1
Exact Sciences Corporation 7.2B 57 67 54 62 50 1
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 51 1
CureVac N.V. 2.6B 45 83 71 74 52 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 53 1
Abgenix Inc. 2.1B 47 47 47 47 54 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 55 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 56 1
Xencor, Inc. 1.6B 42 94 52 79 57 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 58 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 59 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 60 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 61 1
Veracyte, Inc. 1.4B 45 63 57 55 62 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 63 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 64 1
CareDx, Inc 1.2B 61 44 82 50 65 1
Vericel Corporation 1.1B 76 44 82 56 66 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 67 1
MannKind Corporation 957.2M 95 48 56 61 68 1
Merus N.V. 941.6M 48 60 59 54 69 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 70 1
Amarin Corporation plc 734.5M 95 44 82 63 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 72 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 73 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 74 1
CTI BioPharma Corp. 603.6M 84 50 62 59 75 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 77 1
Immatics N.V. 538.7M 37 93 53 77 78 1
Agenus Inc. 520.5M 57 83 45 74 79 1
Radius Health, Inc. 499.8M 94 71 68 82 80 1
Vaxart, Inc. 440.0M 99 51 72 68 81 1
Affimed N.V. 415.0M 95 49 75 66 82 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 83 1
MiMedx Group, Inc. 391.5M 87 43 83 59 84 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 85 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 86 1
Zymeworks Inc. 324.7M 58 53 77 56 87 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 88 1
Silence Therapeutics plc 313.4M 83 64 69 72 89 1
AC Immune SA 299.8M 83 61 65 70 90 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 91 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 92 1
Chimerix, Inc. 178.4M 99 50 62 65 93 1
DermTech, Inc. 165.3M 49 48 78 52 94 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Free Cash flow and Net Cash Flow stand out as the most significant drivers of Ionis Pharmaceuticals's cash flow's strength. Ionis Pharmaceuticals's published free cash flow numbers were substantial and reflected management's focus on a healthy change strategy. Ionis Pharmaceuticals recorded free cash flow of 0.3, which represents a 173.9% change from the previous report. This parameter coud affect companies in the same industry and market capitalization by up to 2.6%. These free cash flow numbers show that management has executed well while generating cash flow and encouraging growth. Therefore, its free cash flow movement earned a score of 96. Also, Ionis Pharmaceuticals presents exciting net cash flow numbers for its recent financial release, illustrated by a net cash flow of 128.4, which is a change of -72.8% from the last filing. This industry-leading net cash flow momentum should reinforce broader positive momentum for its's stock price going forward. The company's net cash flow, therefore, received a grade of 88. That said, one metric, Capital Expenditure, stood out as particularly concerning. Ionis Pharmaceuticals's management was ineffective in materially improving CapEx, which now sits at -12.9 and represents a -7.8% change from the previous report. They appears to be headed in the wrong direction regarding resource allocation, exhibiting prudent capital expenditure growth compared to its peers. Consequently, their CapEx movement received a grade of 60. Their cash flow received an overall score of 89.

Parameter Value Change Score
Net Cashflow 128.4 -72.8% 88
Capital Expenditure -12.9 -7.8% 60
Asset Turnover 0.4 8.8% 86
Free Cashflow 0.3 173.9% 96
* All values are TTM

The below chart describes Ionis Pharmaceuticals's performance as reflected on its cash flow with respect to its peers. While Ionis Pharmaceuticals received a cash flow score of 89, the average of its peers stands on 68.0.

  •  IONS
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Amgen Inc. 130.1B 80 74 67 74 81 0 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 1 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 3 1
BioNTech SE 34.0B 73 97 50 52 72 4 1
Seagen Inc. 32.9B 53 53 50 87 58 5 1
Biogen Inc. 29.7B 58 54 90 73 66 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 7 1
Incyte Corporation 16.8B 78 79 92 74 84 8 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 9 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 10 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 11 1
Exelixis, Inc. 6.7B 79 90 89 83 87 12 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 13 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 14 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 15 1
Alkermes plc 5.0B 89 95 76 80 92 16 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 17 1
Novavax, Inc. 4.0B 62 38 63 54 60 18 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 19 1
Natera, Inc. 3.6B 52 54 56 84 58 20 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 21 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 22 1
Insmed Incorporated 2.4B 79 80 61 89 82 23 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 25 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 27 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 28 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 29 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 30 1
FibroGen, Inc. 1.0B 86 74 48 87 84 31 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 32 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 33 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 35 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 36 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 37 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 38 1
Geron Corporation 566.2M 78 68 49 81 77 39 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 40 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 41 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 42 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 43 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 45 1
Precigen, Inc. 299.1M 82 75 37 85 74 46 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 47 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 48 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 49 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 50 1
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 51 1
CureVac N.V. 2.6B 87 80 90 70 90 52 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 53 1
Abgenix Inc. 2.1B 66 53 45 59 58 54 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 55 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 56 1
Xencor, Inc. 1.6B 96 95 70 95 98 57 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 58 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 59 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 60 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 61 1
Veracyte, Inc. 1.4B 90 95 46 46 82 62 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 63 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 64 1
CareDx, Inc 1.2B 98 84 40 50 86 65 1
Vericel Corporation 1.1B 64 46 59 73 65 66 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 67 1
MannKind Corporation 957.2M 77 56 43 37 66 68 1
Merus N.V. 941.6M 70 71 74 53 71 69 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 70 1
Amarin Corporation plc 734.5M 52 40 74 55 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 72 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 73 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 74 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 75 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 76 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 77 1
Immatics N.V. 538.7M 82 95 56 99 86 78 1
Agenus Inc. 520.5M 57 43 52 77 58 79 1
Radius Health, Inc. 499.8M 64 40 37 56 57 80 1
Vaxart, Inc. 440.0M 72 56 53 38 65 81 1
Affimed N.V. 415.0M 72 57 95 43 74 82 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 83 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 84 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 85 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 86 1
Zymeworks Inc. 324.7M 52 65 45 83 57 87 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 88 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 89 1
AC Immune SA 299.8M 66 77 79 63 68 90 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 91 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 92 1
Chimerix, Inc. 178.4M 80 84 95 47 83 93 1
DermTech, Inc. 165.3M 60 51 45 86 58 94 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.